Literature DB >> 19414081

Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease.

M Meister1, P Choyke, C Anderson, U Patel.   

Abstract

Von Hippel-Lindau disease (VHL) is a rare, autosomal-dominant condition that predisposes patients to developing renal cysts and tumours. VHL is the most common of the hereditary renal cancer syndromes, and is exclusively associated with the clear cell histological subtype of renal cell carcinoma. This review focuses on the genetics, surveillance, and management of complex renal masses in VHL. The current status of renal cyst analysis in general and in the context of VHL is also reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19414081     DOI: 10.1016/j.crad.2008.10.010

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  13 in total

1.  Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel-Lindau disease.

Authors:  Fabio Pomerri; Giuseppe Opocher; Chiara Dal Bosco; Pier Carlo Muzzio; Gisella Gennaro
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

2.  Kidney Tumor in a von Hippel-Lindau (VHL) Patient With Intensely Increased Activity on 68Ga-DOTA-TATE PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Samira M Sadowski; Ulas Bagci; Nicholas J Patronas
Journal:  Clin Nucl Med       Date:  2016-12       Impact factor: 7.794

3.  Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.

Authors:  Pradeep Mettu; Elvira Agrón; Sonia Samtani; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

Review 4.  [Modern imaging of renal tumors - application in diagnostics and therapy. Characterization, operation planning and therapy monitoring of renal lesions].

Authors:  J P Radtke; D Teber; C D Alt; B A Hadaschik; P Hallscheidt
Journal:  Radiologe       Date:  2016-03       Impact factor: 0.635

Review 5.  Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.

Authors:  Alexis Teplick; Megan Kowalski; Jaclyn A Biegel; Kim E Nichols
Journal:  Eur J Pediatr       Date:  2011-01-06       Impact factor: 3.183

6.  Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results.

Authors:  Yoichi Iwamoto; Hideki Kanda; Koichiro Yamakado; Norihito Soga; Kiminobu Arima; Kan Takeda; Yoshiki Sugimura
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

7.  Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors.

Authors:  Amit Tirosh; Neige Journy; Les R Folio; Choonsik Lee; Christiane Leite; Jianhua Yao; William Kovacs; W Marston Linehan; Ashkan Malayeri; Electron Kebebew; Amy Berrington de González
Journal:  Radiology       Date:  2018-10-09       Impact factor: 11.105

8.  Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement.

Authors:  Charlotte Gimpel; E Fred Avni; Luc Breysem; Kathrin Burgmaier; Anna Caroli; Metin Cetiner; Dieter Haffner; Erum A Hartung; Doris Franke; Jens König; Max C Liebau; Djalila Mekahli; Albert C M Ong; Lars Pape; Andrea Titieni; Roser Torra; Paul J D Winyard; Franz Schaefer
Journal:  Radiology       Date:  2019-01-01       Impact factor: 11.105

9.  Radiological considerations in von Hippel-Lindeau disease: imaging findings and the review of the literature.

Authors:  Melda Apaydin; Makbule Varer; Ozgur Oztekin
Journal:  Radiol Oncol       Date:  2010-09-09       Impact factor: 2.991

10.  Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance.

Authors:  Karin Y van Spaendonck-Zwarts; Sadhanna Badeloe; Sjoukje F Oosting; Sjoerd Hovenga; Harry J F Semmelink; R Jeroen A van Moorselaar; Jan Hein van Waesberghe; Arjen R Mensenkamp; Fred H Menko
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.